ArticleEpilepsia open2019
Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy.
Article in Epilepsia open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Movement disorders associated with antiseizure medications: A systematic review.Epilepsy & behavior : E&B · 2022Pooled it
- The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine.The pharmacogenomics journal · 2026Review
- Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics.Brain : a journal of neurology · 2025Article
- Genetic Animal Models of Idiopathic Generalized Epilepsies: What Can We Learn from Them?Biomedicines · 2025Review
- Tremor as an intrinsic feature of juvenile myoclonic epilepsy.Epilepsia · 2025Article
- A meta-analytic evaluation of the efficacy and safety of levetiracetam for treating myoclonic seizures.Heliyon · 2025Article
- Article
- Variation in prognosis and treatment outcome in juvenile myoclonic epilepsy: a Biology of Juvenile Myoclonic Epilepsy Consortium proposal for a practical definition and stratified medicine classifications.Brain communications · 2023Review
- Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis.EClinicalMedicine · 2022Article
- Replacement of Valproic Acid with New Anti-Seizure Medications in Idiopathic Generalized Epilepsy.Journal of clinical medicine · 2022Article
- Seizure control in mono- and combination therapy in a cohort of patients with Idiopathic Generalized Epilepsy.Scientific reports · 2022Article
- Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy.Epilepsia open · 2022Article
- Neuropharmacology of Antiseizure Drugs.Neuropsychopharmacology reports · 2021Review
- Prolonged epileptic discharges predict seizure recurrence in JME: Insights from prolonged ambulatory EEG.Epilepsia · 2021Article
- Efficacy and tolerability of antiseizure drugs.Therapeutic advances in neurological disorders · 2021Review
- Trait impulsivity in Juvenile Myoclonic Epilepsy.Annals of clinical and translational neurology · 2021Article
- Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications.Frontiers in pharmacology · 2021Article
- Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.CNS drugs · 2020Review
- Principles of Epilepsy Management for Women in Their Reproductive Years.Frontiers in neurology · 2020Review
- Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy.Epilepsia open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 16 institutions in 8 countries.
Funding
Abstract
objectiveTo study the effectiveness and tolerability of antiepileptic drugs (AEDs) commonly used in juvenile myoclonic epilepsy (JME).
methodsPeople with JME were identified from a large database of individuals with epilepsy, which includes detailed retrospective information on AED use. We assessed secular changes in AED use and calculated rates of response (12-month seizure freedom) and adverse drug reactions (ADRs) for the five most common AEDs. Retention was modeled with a Cox proportional hazards model. We compared valproate use between males and females.
resultsWe included 305 people with 688 AED trials of valproate, lamotrigine, levetiracetam, carbamazepine, and topiramate. Valproate and carbamazepine were most often prescribed as the first AED. The response rate to valproate was highest among the five AEDs (42.7%), and significantly higher than response rates for lamotrigine, carbamazepine, and topiramate; the difference to the response rate to levetiracetam (37.1%) was not significant. The rates of ADRs were highest for topiramate (45.5%) and valproate (37.5%). Commonest ADRs included weight change, lethargy, and tremor. In the Cox proportional hazards model, later start year (1.10 [1.08-1.13], SIGNIFICANCE: In people with JME, valproate is an effective AED; levetiracetam emerged as an alternative. Valproate is now contraindicated in women of childbearing potential without special precautions. With appropriate selection and safeguards in place, valproate should remain available as a therapy, including as an alternative for women of childbearing potential whose seizures are resistant to other treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.